Literature DB >> 8911536

A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis.

R E Hurst1, J B Roy, K W Min, R W Veltri, G Marley, K Patton, D L Shackelford, P Stein, C L Parsons.   

Abstract

OBJECTIVES: To investigate the abundance of chondroitin sulfate proteoglycans at the bladder lumenal and subepithelial surfaces in bladder biopsies derived from patients with interstitial cystitis (IC) and controls.
METHODS: Tissue sections derived from biopsies from 31 IC patients and 24 pathologically normal control sections were labeled for proteoglycans using the 2B6 anti-"stub" antibody and detected by immunohistochemistry.
RESULTS: On the lumenal surface, 5 of 31 (19%) IC sections were positive for proteoglycans versus 14 of 24 (58%) control sections (P = 0.00011). At the basal surface, 5 of 19 IC patients were positive versus 7 of 12 controls (P = 0.032).
CONCLUSIONS: A deficit of bladder lumenal and basal proteoglycans is associated with IC. The deficit in basal layer proteoglycans suggests an altered urothelial differentiation program. The lumenal deficit suggests that the charge-dependent exclusion of ions from the bladder surface is compromised in IC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911536     DOI: 10.1016/S0090-4295(96)00322-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  32 in total

1.  Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity.

Authors:  Salvatore Siracusano; Antonio Cucchi; Stefano Ciciliato; Nicolitza Lampropoulou; Franco Vittur
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-08-12

Review 2.  Interstitial cystitis.

Authors:  D R Erickson; M F Davies
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 3.  Inflammasomes in the urinary tract: a disease-based review.

Authors:  J Todd Purves; F Monty Hughes
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-11

4.  Fine structural characterization of chondroitin sulfate in urine of bladder pain syndrome subjects.

Authors:  Francesca Maccari; Dania Buzzega; Fabio Galeotti; Nicola Volpi
Journal:  Int Urogynecol J       Date:  2011-08-02       Impact factor: 2.894

5.  The role of pentosan polysulfate in treatment approaches for interstitial cystitis.

Authors:  Joel Mh Teichman
Journal:  Rev Urol       Date:  2002

6.  Efficacy of intravesical chondroitin sulphate in treatment of interstitial cystitis/bladder pain syndrome (IC/BPS): Individual patient data (IPD) meta-analytical approach.

Authors:  Ammarin Thakkinstian; J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

7.  Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients.

Authors:  Ricardo Saban; Marcia R Saban; Julie Maier; Ben Fowler; Mark Tengowski; Carole A Davis; Xue-Ru Wu; Daniel J Culkin; Paul Hauser; Joseph Backer; Robert E Hurst
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

Review 8.  Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome.

Authors:  Marc A Colaco; Robert J Evans
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 9.  Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence.

Authors:  Massimo Lazzeri; Rodolfo Hurle; Paolo Casale; NicolòMaria Buffi; Giovanni Lughezzani; Girolamo Fiorini; Roberto Peschechera; Luisa Pasini; Silvia Zandegiacomo; Alessio Benetti; Gianluigi Taverna; Giorgio Guazzoni; Guido Barbagli
Journal:  Ther Adv Urol       Date:  2015-12-16

10.  Differentiation potential of urothelium from patients with benign bladder dysfunction.

Authors:  Jennifer Southgate; Claire L Varley; Mary A E Garthwaite; Jennifer Hinley; Fiona Marsh; Jens Stahlschmidt; Ludwik K Trejdosiewicz; Ian Eardley
Journal:  BJU Int       Date:  2007-06       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.